G01N 2333/90638
With a definite ec number
Official title: with a definite EC number (1.4.3.-)
G01N2333/90638 (With a definite ec number) appears on 31 US grants and 45 published applications in this corpus.
Search patents in G01N- Granted patents
- 31
- Published applications
- 45
- Assignees
- 33
- Inventors
- 101
- Latest grant
- 28 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 2 |
| 2012 | 0 | 2 |
| 2013 | 2 | 3 |
| 2014 | 2 | 3 |
| 2015 | 1 | 5 |
| 2016 | 3 | 5 |
| 2017 | 3 | 4 |
| 2018 | 5 | 4 |
| 2019 | 1 | 3 |
| 2020 | 5 | 2 |
| 2021 | 2 | 2 |
| 2022 | 1 | 2 |
| 2023 | 0 | 2 |
| 2024 | 1 | 2 |
| 2025 | 1 | 1 |
| 2026 | 4 | 1 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compounds and methods for amine oxidase imaging28 Jul 2026US 12,692,532 B2ETH Zurich
- Methods for assessing risk of cardiovascular disease and methods and compounds for use in treating or preventing cardiovascular disease5 May 2026US 12,616,672 B2Queen Mary University of London
- Bioprobes for lysyl oxidases and uses thereof17 Mar 2026US 12,578,335 B2Syntara Limited
- Sampling method and kit for histamine measurement3 Mar 2026US 12,565,672 B2Kikkoman Corporation
- Energy drinks and other nutritional aids derived from agave-based spirits4 Mar 2025US 12,241,048 B2Roar Holding LLC
- Method for examining feline renal dysfunction17 Sep 2026US 2026/0276649 A1Kao Corporation
- Recombinantly expressed glutamate oxidase10 Apr 2025US 2025/0115883 A1Kikkoman Corporation
- Differential diagnosis of histamine intolerance syndrome4 Jul 2024US 2024/0219399 A1Immundiagnostik AG
- Identification of mitochondria-enriched cells7 Mar 2024US 2024/0076711 A1Minovia Therapeutics Ltd.
- Bioprobes for lysyl oxidases and uses thereof2 Nov 2023US 2023/0349907 A1Pharmaxis Ltd.
Most cited
By later US patents
- Energy drinks and other nutritional aids derived from agave-based spirits5US 10,195,163 B2Roar Holding LLC · 2019
- Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis3US 8,389,709 B2Technion Research & Development Foundation Limited · 2013
- Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis3US 8,815,824 B2Technion Research & Development Foundation Limited · 2014
- Energy drinks and other nutritional aids derived from agave-based spirits2US 11,160,774 B2Roar Holding LLC · 2021
- Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis2US 9,255,271 B2Technion Research & Development Foundation Limited · 2016